Phosphoinositide 3-kinases in lysophosphatidic acid signaling: regulation and cross-talk with the Ras/mitogen-activated protein kinase pathway - PubMed (original) (raw)

Review

Phosphoinositide 3-kinases in lysophosphatidic acid signaling: regulation and cross-talk with the Ras/mitogen-activated protein kinase pathway

Armelle Yart et al. Biochim Biophys Acta. 2002.

Abstract

Recent reports have shown that phosphoinositide 3-kinases (PI3Ks) mediate various biological activities of lysophosphatidic acid (LPA), including cell proliferation or survival. In addition, these enzymes have been proposed to be early intermediates of mitogen-activated protein kinase (MAPK) activation. Here we summarize our current knowledge of the mechanisms underlying these observations. p110gamma is an isoform of PI3K that can be activated in vitro by Gbetagamma subunits and was therefore considered as the logical candidate to mediate responses induced by G protein-coupled receptor (GPCR) agonists. In agreement with this, p110gamma has been involved in different biochemical models linking Gbetagamma to MAPK activation. Nevertheless, its apparent tissue-specific distribution has raised questions regarding the physiological relevance of these models. In addition, LPA can activate p110beta, a member of the phosphotyrosine-dependent PI3K subfamily that participates in the mitogenic effect of LPA. Its activation is thought to involve a synergistic effect of Gbetagamma and phosphotyrosine motifs provided by a transactivated EGF receptor/Gab1 pathway. We are currently studying a possible role of p110beta upstream from Ras, suggesting that this protein could provide a novel connection between betagamma and the MAPK pathway.

PubMed Disclaimer

Cited by

The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets.
Rocca A, Braga L, Volpe MC, Maiocchi S, Generali D. Rocca A, et al. Cancers (Basel). 2022 Oct 28;14(21):5306. doi: 10.3390/cancers14215306. Cancers (Basel). 2022. PMID: 36358725 Free PMC article. Review.
PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression.
Deng S, Leong HC, Datta A, Gopal V, Kumar AP, Yap CT. Deng S, et al. Cancers (Basel). 2022 Mar 24;14(7):1652. doi: 10.3390/cancers14071652. Cancers (Basel). 2022. PMID: 35406424 Free PMC article. Review.
Lysophosphatidic Acid Promotes the Expansion of Cancer Stem Cells via TRPC3 Channels in Triple-Negative Breast Cancer.
Hirata N, Yamada S, Yanagida S, Ono A, Yasuhiko Y, Nishida M, Kanda Y. Hirata N, et al. Int J Mol Sci. 2022 Feb 10;23(4):1967. doi: 10.3390/ijms23041967. Int J Mol Sci. 2022. PMID: 35216080 Free PMC article.
Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.
Xu Y. Xu Y. Cancers (Basel). 2019 Oct 10;11(10):1523. doi: 10.3390/cancers11101523. Cancers (Basel). 2019. PMID: 31658655 Free PMC article. Review.
RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms.
Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS, Diefenbacher M, Stamp G, Downward J. Fritsch R, et al. Cell. 2013 May 23;153(5):1050-63. doi: 10.1016/j.cell.2013.04.031. Cell. 2013. PMID: 23706742 Free PMC article.

Phosphoinositide 3-kinases in lysophosphatidic acid signaling: regulation and cross-talk with the Ras/mitogen-activated protein kinase pathway - PubMed (original) (raw)